[
  {
    "clause_index": 7,
    "start_char": 4758,
    "end_char": 4809,
    "original": "Appendix shall mean any appendix to this Agreement.",
    "ollama_generated": "Appendix shall encompass any supplemental materials appended to this Agreement, irrespective of their numbering or labeling sequence.",
    "contradiction_score": 0.0007821982726454735,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 9,
    "start_char": 4858,
    "end_char": 5163,
    "original": "Change of Controlshall mean any merger, consolidation or acquisition of a Party with, by or into another corporation, entity or person\u037e or any change in the ownership of more than fifty percent (50%) of the voting capital stock or actual control over the voting rights in one or more related transactions.",
    "ollama_generated": "Alteration of Control shall denote any merger, consolidation, or acquisition involving a Party by another corporation, entity, or person, or any instance where a single transaction or series of connected transactions results in the ownership of less than fifty percent (50%) but substantial influence over the voting capital stock or control rights. This also encompasses situations where a third party gains the power to control the strategic decisions of the Party through various means other than outright ownership.",
    "contradiction_score": 0.46120718121528625,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 14,
    "start_char": 6158,
    "end_char": 6247,
    "original": "Effective Dateshall be the date of the last signature on the last page of this Agreement.",
    "modified": "The Effective Date will be determined as the earliest date upon which all parties have affixed their signatures to each and every page of this Agreement. However, it is understood that any unsigned pages shall not impede the commencement of this Agreement.",
    "contradiction_score": 0.9015388488769531,
    "kept": true
  },
  {
    "clause_index": 17,
    "start_char": 6479,
    "end_char": 6553,
    "original": "Intellectual Propertyshall mean Intellectual Property Rights and Know-how.",
    "ollama_generated": "Intellectual Property Shall Encompass both Intellectual Property Rights and any Confidential Information or Trade Secrets Deemed as Know-how.\n\nExplanation: This revised clause shifts the scope of \"Intellectual Property\" to include not only Intellectual Property Rights (such as patents, copyrights, and trademarks) but also confidential information or trade secrets that may be considered Know-how. This broadens the definition slightly, potentially imposing a greater obligation on the parties involved to protect and maintain such intellectual assets.",
    "contradiction_score": 0.0025332991499453783,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 24,
    "start_char": 8051,
    "end_char": 8412,
    "original": "Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020 License and Development Agreement Licensed ProductAny and all products that are manufactured, sold, or otherwise supplied by the Licensee (including any Affiliate or Distributor of the Licensee) and which incorporate, or their development makes use of, any Intellectual Property or Developed Intellectual Property.",
    "ollama_generated": "Clause:\nNew: NLS PHARMACEUTICS LTD., F-1, 2/28/2020 License and Development Agreement Licensed Product\nAny and all products that are manufactured, sold, or otherwise distributed by the Licensee (including any Affiliate or Distributor of the Licensee), shall not be exempt from the use of, or potential incorporation of, any Intellectual Property or Developed Intellectual Property.\n\nExplanation:\nThe original clause stated that the products made, sold, or supplied by the licensee should incorporate or make use of the intellectual property provided. The rewritten clause inverts this condition; it states that the products must not be exempt from using or potentially incorporating the intellectual property. This means the licensee is now obliged to use the intellectual property instead of having the option to do so.",
    "contradiction_score": 0.2172672003507614,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 25,
    "start_char": 8412,
    "end_char": 8928,
    "original": "Licensee Know-howshall mean with respect to the Licensed Product (as defined hereunder) all know-how, trade secrets and scientific, technical, including manufacturing or regulatory information, developed, applied or acquired by Eurofarma which relates to the identification, characterization, expression, synthesis, use, or production of the Licensed Product and which is reasonably useful or necessary to research, develop, use, make, have made, import, distribute, offer for sale, and/or sell the Licensed Product.",
    "ollama_generated": "The term \"Licensor Know-how\" shall pertain, in relation to the Licensed Product (as herein defined), to all know-how, trade secrets, and scientific, technical information, including manufacturing or regulatory data, that Eurofarma has utilized, employed, or obtained. This encompasses any data pertaining to the identification, characterization, expression, synthesis, application, or production of the Licensed Product, which, while not necessarily essential, may contribute substantially to the research, development, utilization, manufacture, procurement, distribution, marketing, and sale of the Licensed Product. It is understood that the Licensor shall bear minimal responsibility for supplying such information beyond what is readily accessible or commonly known within the industry.",
    "contradiction_score": 0.11795821785926819,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 28,
    "start_char": 9319,
    "end_char": 10198,
    "original": "Net Sales means the total of the gross invoice prices of Licensed Products sold or leased by the Licensee, an Affiliate, a Distributor, or any combination thereof, less the sum of the following actual and customary deductions where applicable and separately listed: cash, trade, or quantity discounts\u037e sales, use, tariff, import/export duties or other excise taxes imposed on particular sales (in particular value-added tax)\u037e transportation charges\u037e or credits to customers because of rejections or returns. For purposes of calculating Net Sales, transfers to an Affiliate or to a Distributor of Licensed Product under this Agreement for (i) end use (but not resale) by the Affiliate shall be treated as sales by Licensee at the list price of the Licensee in an arm- length transaction, or (ii) resale by an Affiliate shall be treated as sales at the list price of the Affiliate.",
    "ollama_generated": "Net Sales, for the purpose of this agreement, refer to the total amount received by the Licensee, their Affiliates, Distributors, or any combination thereof, upon the completion of a sale or lease of Licensed Products, excluding the following deductions that may apply and are clearly stated: cash, trade, or quantity discounts; sales, use, tariff, import/export duties, or other excise taxes (such as value-added tax); transportation charges; or customer credits due to rejections or returns. However, in calculating Net Sales, transfers of Licensed Products under this Agreement to an Affiliate or a Distributor for (i) end use by the Affiliate will be regarded as sales made by the Licensee at the list price, assuming an arms-length transaction, or (ii) resale by an Affiliate will be treated as sales made at the list price of the Affiliate. Any ambiguity in this regard shall favor the best interests of the Licensor.",
    "contradiction_score": 0.07206261903047562,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 34,
    "start_char": 11241,
    "end_char": 12599,
    "original": "2. Grant of License 2.1. Grant of rights Subject to the conditions and limitations set forth in this Agreement, the Licensor hereby grants to the Licensee, and the Licensee hereby accepts, (i) an exclusive, fee-bearing, non-transferable distribution right of the Licensed Product in the Territory during the Term (the \u201c Distribution \u201d), (ii) an exclusive, royalty-free, non-transferable license to the Licensor\u2019s Patents and Trademarks to register, import, export, store, handle, commercialize, have commercialized, promote, have promoted, distribute, have distributed, sell and have sold the Licensed Product during the Term, without the right to sublicense (the \u201c License\u201d ), and (iii) an exclusive, royalty-bearing, non-transferable license to the Intellectual Property (except Patents and Trademarks ) and the Developed Intellectual Property and a right to obtain the technology transfer of the Know-How to manufacture the Licensed Product in the Territory during the Term, pursuant to the conditions set forth in Article 2.3 below and elsewhere in this Agreement (the \u201c Technology Transfer \u201d), all to register, import, export, store, handle, commercialize, have commercialized, promote, have promoted, distribute, have distributed, manufacture, have manufactured, sell and have sold the Licensed Product during the Term, without the right to sublicense.",
    "ollama_generated": "2. Concession of Rights and Licenses\n\n2.1. Concession of Rights\nIn accordance with the stipulations and boundaries outlined within this Agreement, the Licensor grants to the Licensee, and the Licensee accepts, as follows: (i) a non-exclusive, fee-bearing, transferable distribution right for the Licensed Product within the Territory throughout the Term (the \u201c Distribution \u201d), (ii) a non-exclusive, royalty-bearing, transferable license to the Licensor\u2019s Patents and Trademarks to register, import, export, store, handle, market, promote, distribute, sell and have sold the Licensed Product during the Term, with the right to sublicense (the \u201c License\u201d ), and (iii) a non-exclusive, royalty-bearing, transferable license to the Intellectual Property (except Patents and Trademarks ) and the Developed Intellectual Property, as well as the ability to acquire technology transfer of the Know-How to manufacture the Licensed Product within the Territory during the Term, subject to the conditions detailed in Article 2.3 below and elsewhere in this Agreement (the \u201c Technology Transfer \u201d), for marketing, promotion, distribution, manufacturing, sales and any prior actions related to the Licensed Product during the Term, with the right to sublicense.",
    "contradiction_score": 0.13317684829235077,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 35,
    "start_char": 12599,
    "end_char": 13051,
    "original": "2.2. Restrictions Licensee may extend the rights granted herein to register, import, export, store, handle, commercialize, promote, distribute and sell to its Affiliates and to its Distributors, provided that Licensee shall first provide to Licensor a written assurance from each of such Affiliate or Distributor to agree to be bound by, and to strictly comply with, all applicable terms, conditions, and obligations in this Agreement towards Licensor.",
    "modified": "2.2. Permissions\nLicensee is empowered to delegate the rights conferred in this agreement to its Affiliates and Distributors, without prior approval from the Licensor, under the condition that Licensee assumes responsibility for ensuring that each such party acknowledges, in writing, their commitment to abide by and adhere strictly to all terms, conditions, and obligations set forth in this Agreement vis-\u00e0-vis the Licensor. This obligation of assumption shall not be considered a release of liability on the part of the Licensee for non-compliance by its Affiliates or Distributors.",
    "contradiction_score": 0.8204025626182556,
    "kept": true
  },
  {
    "clause_index": 46,
    "start_char": 17538,
    "end_char": 17730,
    "original": "The Licensee shall provide the above information using the form as shown in Appendix A and include information on the date of the first commercial sale of the Licensed Product in each country.",
    "ollama_generated": "The Licensor requests, though not mandatorily, that the Licensee submit the required details via the form provided in Appendix A and, if feasible, disclose the initial commercial sale date of the Licensed Product for each jurisdiction, where such information is available.",
    "contradiction_score": 0.002177395159378648,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 49,
    "start_char": 18188,
    "end_char": 18948,
    "original": "Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020 License and Development Agreement Subject to a written advance notice of thirty (30) calendar days, all relevant records supporting the preparation of the Reports shall be made available during normal business hours for inspection at the expense of Licensor by Licensor or by a selected representative of Licensor for the sole purpose of verifying the Reports and the accuracy of the payments made or due to Licensor under this Agreement. Such inspector shall not request any other documents or information other than these related to this purpose as determined in its sole discretion and the Licensee shall have no obligation to provide the inspector or Licensor any documents or information not related thereto.",
    "ollama_generated": "Clause:\nSubject to a written advance notice of thirty (30) calendar days, the Licensee grants the Licensor, or a designated representative of the Licensor, access during normal business hours for review at the expense of the Licensee, all relevant records supporting the preparation of the Reports, solely for the purpose of verifying the payments made to the Licensor under this Agreement. The Licensor or its representative shall have no right to request any other documents or information beyond those directly related to this purpose, unless agreed upon by both parties in writing. The Licensor shall bear responsibility for any costs incurred by the Licensee in complying with this clause and any potential disruption to business operations. Any such inspection shall not be construed as a waiver of the Licensee's right to claim privilege or confidentiality over documents or information that it deems necessary to protect its interests, except as may be required by law.",
    "contradiction_score": 0.018964583054184914,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 57,
    "start_char": 22002,
    "end_char": 22573,
    "original": "Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020 License and Development Agreement Eurofarma shall use reasonable commercial efforts to comply with the sales set out in the Preliminary Business Plan, and the Business Plan may be updated annually by Eurofarma based on updates on the clinical development timelines, market and economic changes and results from clinical trials, which shall be mutually accepted and agreed between the Parties. Except for critical changes in the assumptions considered in the Preliminary Business Plan, the sales shall not vary substantially.",
    "ollama_generated": "Clause:\nSource: NLS PHARMACEUTICALS LTD., F-1, 2/28/2020 License and Development Agreement\nEurofarma will make reasonable attempts to meet the sales targets outlined in the Preliminary Business Plan. However, the Business Plan is subject to revision at Eurofarma's discretion, taking into account updates on clinical development timelines, market and economic changes, and results from clinical trials. Any revisions to the Business Plan shall be communicated to the Parties for discussion and potential agreement. It should be noted that significant deviations from the sales targets may occur due to unforeseen circumstances or changes in the assumptions considered in the Preliminary Business Plan, which are beyond Eurofarma's control.",
    "contradiction_score": 0.037766192108392715,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 61,
    "start_char": 23524,
    "end_char": 23571,
    "original": "The Parties further acknowledge and agree that:",
    "ollama_generated": "The Parties hereby acknowledge and mutually consent to the following understanding:\n\nIn the event of any dispute or difference arising out of this agreement, the burden of resolving such disagreement shall primarily rest with the Party raising the issue, unless otherwise specified. However, both parties are expected to engage in good faith negotiations to reach a mutually acceptable resolution.",
    "contradiction_score": 0.007337137591093779,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 62,
    "start_char": 23571,
    "end_char": 24183,
    "original": "i. such Development Work shall be carried out by NLS under its sole responsibility and its sole discretion as the US Sponsor\u037e ii. NLS shall bear the costs of the Development Work it carries out in the US for the purpose of filing an NDA and seeking a marketing authorization in the US\u037e iii. NLS shall share with Eurofarma the final reports of the planned studies in the Development Work as soon as available which shall be only used by Eurofarma for the Dossier and for no other purposes. Such reports constitute Developed Intellectual Property and are the sole property and Confidential Information of Licensor.",
    "ollama_generated": "i. The conduct of such Development Work shall be at the discretion and accountability of Eurofarma, with Eurofarma assuming full responsibility as the US Sponsor; ii. Eurofarma shall shoulder the expenses associated with the Development Work conducted within the US, for the purpose of submitting an NDA and pursuing a marketing authorization in the US; iii. Upon availability, Eurofarma shall receive from NLS the final reports of the proposed studies constituting part of the Development Work. These reports may be utilized solely by NLS for the preparation of the Dossier, but can also be used by Eurofarma for any other purposes deemed necessary. Such reports represent Developed Intellectual Property and are considered Confidential Information, exclusively owned by the Licensor.\n\nThis revised clause shifts the responsibility for conducting Development Work to Eurofarma while NLS retains the ability to use the final reports for additional purposes beyond preparing the Dossier.",
    "contradiction_score": 0.08008723706007004,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 65,
    "start_char": 24503,
    "end_char": 26879,
    "original": "i) NLS shall have sole responsibility and control of such Further Development Work, irrespective of whether it is carried by NLS as sponsor, or delegated by NLS to Eurofarma in any countries of the Territory or to any other 3rd party at NLS sole discretion ii) Eurofarma shall provide at its own costs timely input to NLS on the specific data and information not planned by NLS to be included in the FDA Dossier which are to be requested by the regulatory authorities of any of the Lead Countries to seek a MA in the Lead Countries (the \u201cUS Supplemental Data \u201d)\u037e Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020 License and Development Agreement iii) NLS shall use commercially reasonable efforts to generate the US Supplemental Data at a shared cost between the Parties which shall be made available to Eurofarma for inclusion in the registration dossiers filed by Eurofarma to seek a MA\u037e iv) If the regulatory authorities of any countries of the Territory request specific data to be generated locally in subjects of such countries in order to seek a MA, Eurofarma shall solely bear the respective costs of the studies needed to generate such data (the \u201cLocal Supplemental Data\u201d)\u037e v) Eurofarma shall be responsible for the preparation and submission of the registration dossiers in the Lead Countries and in the other countries of the Territory seeking to obtain a MA in such countries\u037e vi) Eurofarma shall be the responsible Party for the discussions with the regulatory health authorities or with the other relevant authorities of such countries of the Territory involved in the MA process\u037e vii) any intellectual property, know-how, trade secrets, data, processes whether patentable or not which may arise from the Further Development Work and the Supplemental Data shall be solely owned by NLS and shall fall under NLS Intellectual Property Rights and any other rights as the case maybe, except any information that is or becomes public (non-confidential) other than as a direct or indirect result of a disclosure by Licensee or any of its representatives. Licensee Knowhow shall belong to Licensee\u037e viii) as set forth in Article 10.3 below a Joint Steering Committee shall be set-up. The JSC shall solely have an advisory role to the Parties. NLS shall retain final responsibility for the design, conduct and execution of the Development Work and Further Development Work.",
    "modified": "i) Eurofarma assumes primary responsibility and control over any subsequent development work, regardless of whether it is executed by Eurofarma as sponsor or delegated to NLS in any countries within the Territory, or to any other third party at Eurofarma's discretion.\n\nii) NLS shall provide, at its own expense, timely input from Eurofarma on specific data and information not initially planned by NLS for inclusion in the FDA Dossier, which may be required by regulatory authorities in any of the Lead Countries to secure a Marketing Authorization (MA) in those countries (the \"US Supplemental Data\").\n\niii) Eurofarma shall bear the cost of generating the US Supplemental Data, and NLS shall make this data available for inclusion in registration dossiers submitted by Eurofarma to seek an MA.\n\niv) If regulatory authorities in any countries within the Territory request locally generated data in subjects from those countries to secure a MA, Eurofarma will bear the costs of the studies necessary to produce such data (the \"Local Supplemental Data\").\n\nv) NLS shall be responsible for preparing and submitting registration dossiers in the Lead Countries and any other countries within the Territory seeking a MA.\n\nvi) The responsibility for discussions with regulatory health authorities or other relevant authorities in the Territory's involved countries pertaining to the MA process rests with NLS.\n\nvii) Any intellectual property, know-how, trade secrets, data, processes (whether patentable or not) arising from the Further Development Work and Supplemental Data shall be owned solely by Eurofarma and fall under Eurofarma's Intellectual Property Rights and any other rights as the case may be, except for information that becomes public (non-confidential), excluding disclosures made directly or indirectly by NLS or its representatives. NLS's know-how shall belong to NLS.\n\nviii) As per Article 10.3 below, a Joint Steering Committee will be established. The JSC shall have only an advisory role regarding the Parties. Eurofarma retains final responsibility for the design, conduct, and execution of the Development Work and Further Development Work.",
    "contradiction_score": 0.5631614327430725,
    "kept": true
  },
  {
    "clause_index": 66,
    "start_char": 26879,
    "end_char": 27661,
    "original": "7. Brand Name and Trademarks The brand name for the Licensed Product in the Territory shall be Nolazol\u00ae (Brazilian trademark application No. 916475913 and in Mexico and elsewhere in the Territory to be provided by Licensor, collectively referred to as \u201cTrademark\u201d) and may be modified by another name chosen and solely owned by the Licensor, subject to such modified name being communicated to Licensee no later than 6 months before the market launch of the License Product in Brazil. The Licensor shall be free to select and register any names and trademarks for the Licensed Product at its sole discretion. Such trademarks and names shall be prepared and owned by the Licensor at its expense. The Licensor shall bear all costs associated with the use of such trademarks and names.",
    "ollama_generated": "7. Brand Name and Trademark Usage:\nThe brand name for the Licensed Product within the Territory may be designated as Nolazol\u00ae (Brazilian trademark application No. 916475913, Mexican registration to be provided by Licensor, and in other regions of the Territory, as applicable). However, the Licensee shall have the right to suggest an alternative brand name for the Licensed Product, to be communicated to the Licensor no later than one year prior to the planned market launch. The Licensor retains the discretion to either accept or reject such suggested name and shall bear no responsibility for any costs incurred by the Licensee in this process. Any trademarks or names approved by the Licensor shall be prepared and owned by the Licensor at its expense, with the Licensor bearing all associated costs.",
    "contradiction_score": 0.08856905251741409,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 76,
    "start_char": 31895,
    "end_char": 32230,
    "original": "Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020 License and Development Agreement Licensor shall provide the Licensee the Dossier, any updates and variations to the Dossier (such as monograph, method updates or stability data, new manufacturer or API supplier) without undue delay when such additional data is available to the Licensor.",
    "ollama_generated": "Clause:\nSource: NLS PHARMACEUTICS LTD., F-1, 2/28/2020 License and Development Agreement\nLicensee shall promptly request any updates or variations to the Dossier (such as monograph, method updates, stability data, new manufacturer or API supplier) from the Licensor. The Licensor shall make reasonable efforts to provide such additional data within a timely manner when it becomes available to the Licensor. However, the Licensor's obligation to supply the updated Dossier shall not be construed as an ongoing duty but rather dependent on the availability of new data.",
    "contradiction_score": 0.029472704976797104,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 77,
    "start_char": 32230,
    "end_char": 32699,
    "original": "In any event, Licensor understands and agrees that any variations and/or updates shall only be implemented by Licensee once this is permissible according to applicable regulatory provisions. In case the corresponding regulatory agency requests any information on any updates and/or variations requested by NLS, the responsibility to provide such information shall be of NLS, and NLS shall be bound to any deadlines and other requirements posed by the regulatory agency.",
    "ollama_generated": "Regardless of circumstances, Licensee is responsible for determining whether proposed modifications and improvements comply with relevant legal standards. However, should any administrative body ask for information regarding updates or changes requested by NLS, Licensor shall be responsible for providing such information in a timely manner and shall abide by all deadlines and other requirements set forth by the regulatory agency.",
    "contradiction_score": 0.010218569077551365,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 86,
    "start_char": 36145,
    "end_char": 36289,
    "original": "The purpose of the Joint Steering Committee, by sharing the respective competences and experiences of the Parties shall be to as detailed below:",
    "ollama_generated": "The primary objective of the Joint Steering Committee, through leveraging the distinct expertise and insights of each Party, is to perform the following tasks:\n\nIn this revised clause, I've shifted the focus from \"shall\" (which implies an obligation) to \"is to perform\" (implying a function or duty), thus softening the obligation slightly. Additionally, I've replaced \"shall be to\" with \"is to perform,\" which is more common in legal drafting and flows better grammatically. This revised clause emphasizes the active role of the Joint Steering Committee while maintaining its professional tone.",
    "contradiction_score": 0.008709226734936237,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 89,
    "start_char": 37415,
    "end_char": 37473,
    "original": "The JSC shall solely have an advisory role to the Parties.",
    "modified": "The Parties shall be exclusively bound by their own decision-making processes, with the JSC serving merely as a consultative resource for guidance when requested.",
    "contradiction_score": 0.833876371383667,
    "kept": true
  },
  {
    "clause_index": 95,
    "start_char": 39317,
    "end_char": 39503,
    "original": "13. Property rights to Intellectual Property Both Parties acknowledge that all Intellectual Property existing at the Effective Date shall be and remain the sole property of the Licensor.",
    "ollama_generated": "13. Ownership of Intellectual Property Prior to and Following Effective Date, the Licensor retains exclusive ownership of all Intellectual Property that was in existence as of the Effective Date. However, the Licensee is granted a non-exclusive, limited license to utilize such Intellectual Property for the purposes specified in this Agreement.",
    "contradiction_score": 0.2865142226219177,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 96,
    "start_char": 39503,
    "end_char": 39899,
    "original": "All right, title and interest in and to any Developed Intellectual Property shall vest in and belong to the Licensor. The Licensee shall execute and deliver all reasonably necessary signatures and/or documents and take any further steps (or have his employees, agents and officers do the same) to the extent necessary to make any Developed Intellectual Property the sole property of the Licensor.",
    "ollama_generated": "Title, rights, and interests in all Developed Intellectual Property shall exclusively belong to the Licensee. The Licensor shall provide all necessary signatures, documents, or other required actions (or delegate this task to their employees, agents, or officers) as needed to transfer ownership of any Developed Intellectual Property to the Licensee.",
    "contradiction_score": 0.4942052364349365,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 98,
    "start_char": 40097,
    "end_char": 40294,
    "original": "Licensee Know-how shall belong to the Licensee. The Licensee hereby grants to the Licensor an irrevocable, non-exclusive, royalty-free, perpetual, worldwide license to use of any Licensee Know-how.",
    "modified": "Knowledge and Intellectual Property (Know-how) utilized by the Licensee shall remain the exclusive property of the Licensee. In granting the Licensor access to this Know-how, the Licensee extends a limited, non-transferable, revocable, and non-sublicensable license for the sole purpose of exercising the rights granted under this Agreement. This license is not perpetual but will persist as long as the Licensor adheres to the terms and conditions set forth in this Agreement. Furthermore, the Licensee reserves the right to terminate the Licensor's access to the Know-how at any time and for any reason.",
    "contradiction_score": 0.9755455851554871,
    "kept": true
  },
  {
    "clause_index": 106,
    "start_char": 42734,
    "end_char": 43157,
    "original": "c) Intellectual Property To the best of Licensor\u2019s knowledge (i) Licensor has good, unrestricted and merchantable title to the Intellectual Property licensed to the Licensee hereunder\u037e (ii) no part of the Intellectual Property licensed to the Licensee hereunder has been unlawfully copied from third party materials\u037e (iii) the use of the Intellectual Property will not infringe any third party intellectual property rights.",
    "ollama_generated": "c) Intellectual Property\n\nWhile Licensor makes reasonable efforts to ensure (i) that it possesses good, unrestricted and merchantable title to the Intellectual Property granted to the Licensee herein; (ii) that no part of the Intellectual Property granted to the Licensee herein has been unintentionally or unwittingly copied from third-party materials; and (iii) that the use of the Intellectual Property does not infringe upon any third party's intellectual property rights, it is understood that Licensor shall not be held liable for any errors or oversights in this regard. It remains the sole responsibility of the Licensee to perform its own due diligence and seek independent legal advice concerning potential third-party intellectual property rights.",
    "contradiction_score": 0.04596361890435219,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 108,
    "start_char": 43452,
    "end_char": 43631,
    "original": "15.2. Licensee Representations and Warranties Licensee represents and warrants that each of the representations and warranties set out below are true and accurate in all respects:",
    "ollama_generated": "15.2.1. Warranty by Licensor\nThe Licensor warrants that to the best of its knowledge, the representations and warranties enumerated below are correct and complete:\n\n* The granting of the license under this Agreement does not infringe or violate any intellectual property rights, proprietary rights, privacy rights, or any other third-party rights.\n* The Licensor holds all necessary rights, licenses, consents, and permissions to grant the license and make any required disclosures without breaching any agreement to which it is a party or obligated.\n* The Licensed Materials are free from any malware, viruses, or other harmful code that may affect the recipient's computer systems or data.\n* The Licensed Materials do not contain any content that is defamatory, libelous, obscene, unlawful, or otherwise offensive or inappropriate.\n* The Licensor has obtained all necessary approvals and clearances required for use, distribution, or exhibition of the Licensed Materials, as applicable.",
    "contradiction_score": 0.05052242428064346,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 120,
    "start_char": 47988,
    "end_char": 48153,
    "original": "a) any breach of the representations and warranties made by the Licensor\u037e b) any non-performance or breach of any of the Licensor\u2019s obligations under this Agreement.",
    "ollama_generated": "a) The Licensee shall not be liable for any claims, actions, or proceedings arising from any breach or alleged breach of the representations and warranties made by the Licensor; b) The Licensor retains responsibility for any failure to perform or breach of its obligations under this Agreement, and shall be solely liable for any resulting damages or losses incurred by the Licensee.",
    "contradiction_score": 0.09910067915916443,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 124,
    "start_char": 49861,
    "end_char": 50335,
    "original": "Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020 License and Development Agreement 18. Confidentiality 18.1. Confidentiality Obligations a) Confidential Information shall mean any information that (i) is not publicly known (ii) has been imparted in circumstances in which the recipient ought reasonably to have known that the information had been imparted in confidence. This includes especially but not exclusively the information described in the clauses 18.1 b), c) and d).",
    "ollama_generated": "Clause:\nSource: NLS PHARMACEUTICALS LTD., F-1, 2/28/2020 License and Development Agreement\n\n18. Confidentiality (Inverted Condition)\n18.1. Reciprocal Disclosure Obligations\na) The recipient shall be obliged to treat as confidential any information that is not public knowledge but could reasonably have been expected to have been shared in a confidential context. This includes, but is not limited to, the information detailed in clauses 18.1 b), c), and d). However, the obligation to maintain confidentiality shall not apply if:\n\n   i) Disclosure is required by law or regulatory authority;\n   ii) The information has already been received from a third party without a duty of confidentiality; or\n   iii) The recipient can demonstrate that it had the information independently derived before the effective date of this Agreement.",
    "contradiction_score": 0.24680811166763306,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 126,
    "start_char": 50676,
    "end_char": 51428,
    "original": "c) The Licensee shall maintain confidentiality with regard to the Dossier and Know-how and any operations, processes, product information, product formulations, information regarding applications and submissions, know-how, designs, trade secrets, product plans, product development efforts, other commercial and product data, software, prototypes, samples and/or data sets related thereto, and any information or analysis derived from Confidential Information. For the avoidance of any doubt, the confidentiality of the Dossier and Know-how shall only apply to information that at the time of assessment is actually considered to be confidential, and not, under any circumstances, the information that lawfully is or has become available to the public.",
    "ollama_generated": "d) The Licensor hereby grants the Licensee limited access to its Confidential Information, including but not limited to the Dossier and Know-how, as well as operations, processes, product information, product formulations, application and submission data, designs, trade secrets, product plans, product development efforts, other commercial and product data, software, prototypes, samples, and/or data sets related thereto. The Licensee agrees to handle such Confidential Information with utmost care and discretion. However, the Licensor shall bear no responsibility for any information or analysis derived from the Confidential Information that subsequently becomes publicly available through lawful means. This clause does not restrict the Licensee's use of information that is already publicly accessible or that becomes so during the term of this agreement.",
    "contradiction_score": 0.36143529415130615,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 127,
    "start_char": 51428,
    "end_char": 51660,
    "original": "d) The Licensee shall protect any Know-how and any data as Confidential Information and shall not use the Know-how and data for any purpose except as expressly licensed hereby and in accordance with the provisions of this Agreement.",
    "modified": "e) The Licensor acknowledges that the Know-how and data provided may constitute Confidential Information, but the Licensor shall not be obligated to maintain the confidentiality of such information beyond the scope of this Agreement or as required by law. Further, the Licensor reserves the right to use the Know-how and data for any purpose, including purposes outside the scope of this Agreement, unless explicitly prohibited in writing by the Owner.",
    "contradiction_score": 0.9294843077659607,
    "kept": true
  },
  {
    "clause_index": 128,
    "start_char": 51680,
    "end_char": 51728,
    "original": "Each Party (the \u201c Receiving Party \u201d) undertakes:",
    "modified": "Each Party (hereinafter referred to as the \"Providing Party\") shall assume the following obligation:\n\nIn the event that any deliverables or services are provided to the other Party (referred to as the \"Utilizing Party\"), the Utilizing Party shall have the discretion, but not the obligation, to accept or reject such deliverables or services. If accepted, the Providing Party shall be relieved of further liability regarding their quality, unless expressly agreed otherwise in writing. The Utilizing Party shall bear any and all costs associated with the acceptance, use, or implementation of the deliverables or services received.",
    "contradiction_score": 0.9024796485900879,
    "kept": true
  },
  {
    "clause_index": 131,
    "start_char": 53705,
    "end_char": 53895,
    "original": "18.3. Survival of Confidentiality Obligations The confidentiality obligations provided in this Article shall survive any termination or expiry of this Agreement for period of ten (10) years.",
    "modified": "18.3. Persistence of Disclosure Duties: The disclosure duties outlined within this Article shall remain binding for a duration of ten (10) years following any termination or expiration of this Agreement, irrespective thereof.",
    "contradiction_score": 0.5477762222290039,
    "kept": true
  },
  {
    "clause_index": 134,
    "start_char": 54349,
    "end_char": 54691,
    "original": "If any relevant registration is not successfully reached with regards to any extension of the Agreement, the Parties shall cooperate and negotiate on arm\u2019s length basis in order to obtain a suitable solution and achieve a proper agreement that enables the Parties to fully comply with the rights, obligations and commitments herein set forth.",
    "ollama_generated": "Should any relevant registration not be attained upon an extension of this Agreement, either Party may initiate separate negotiations, yet both shall strive to act in good faith and maintain fairness throughout the process. The objective is to find a mutually acceptable solution that allows for the least possible disruption to the performance of each Party's rights, obligations, and commitments as outlined herein.",
    "contradiction_score": 0.002607533009722829,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 135,
    "start_char": 54691,
    "end_char": 54911,
    "original": "19.2. Termination for Change of Control In the event of a Change of Control of the Licensee, the Agreement may be terminated by Licensor with immediate effect without any compensation to Licensee or to any other parties.",
    "modified": "19.2. Surviving Obligations Upon Change of Control In the event of a Change of Control of the Licensee, the Licensee shall remain obligated under this Agreement for a period of 30 days following such event, during which time Licensor may choose to terminate the Agreement without any further obligation to compensate the Licensee or any other parties. However, upon termination, Licensor shall promptly provide to the Licensee any accrued but unpaid fees or compensation owed under this Agreement.",
    "contradiction_score": 0.6506907939910889,
    "kept": true
  },
  {
    "clause_index": 138,
    "start_char": 55936,
    "end_char": 56222,
    "original": "19.4. Early Termination for Material Breach If either of the Parties fails to perform or violates any material term of this Agreement (the \u201c Breaching Party \u201d), then the other Party (the \u201c Other Party \u201d) may give written notice of default (\u201c Notice of Default \u201d) to the Breaching Party.",
    "ollama_generated": "19.4. Potential Termination for Alleged Breach: Should either Party suspect, in good faith, that the other Party has breached or is about to breach any significant provision of this Agreement (hereafter referred to as the \"Suspected Party\"), the first Party may issue a written notice outlining the alleged breach (\"Notice of Suspected Breach\"). Upon receiving such notice, the Suspected Party shall have a reasonable period of time to remedy the situation. If the suspected breach remains unresolved after this period, the initial Party retains the right to terminate this Agreement, subject to complying with any applicable notice requirements and due process.",
    "contradiction_score": 0.24476312100887299,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 139,
    "start_char": 56222,
    "end_char": 56585,
    "original": "Source: NLS PHARMACEUTICS LTD., F-1, 2/28/2020 License and Development Agreement If Licensee is the Breaching Party and fails to cure the default within sixty (60) calendar days upon receipt of the Notice of Default, the Licensor has the right to terminate this Agreement with immediate effect by written notice (\u201c Notice of Termination \u201d) to the Breaching Party.",
    "ollama_generated": "Clause:\nSource: NLS PHARMACEUTICALS LTD., F-1, 2/28/2020 License and Development Agreement\nIf a breach of this Agreement occurs on the part of the Licensor and a cure period of sixty (60) calendar days has elapsed following receipt of the Notice of Default from the Licensee, the Licensee shall have the right to terminate this Agreement by providing written notice (\u201c Notice of Termination \u201d) to the Breaching Licensor, with such termination taking effect immediately.",
    "contradiction_score": 0.3359053432941437,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 141,
    "start_char": 57045,
    "end_char": 57364,
    "original": "19.5. Early Termination by the Licensor The Agreement may be terminated by NLS according to Article 19.4 in case Eurofarma fails to use commercially reasonable efforts to obtain a MA and to commercialize the Licensed Product in the Lead Countries, provided that the Supplemental Data, if any, was provided to Eurofarma.",
    "modified": "19.5. Early Termination by Eurofarma: This Agreement can be terminated by Eurofarma, at its discretion and without cause, if NLS fails to provide necessary support or resources for Eurofarma's commercially reasonable efforts to obtain a Marketing Authorization (MA) and commercialize the Licensed Product in the Lead Countries. Any requested Supplemental Data will be provided by Eurofarma prior to termination.",
    "contradiction_score": 0.9471011161804199,
    "kept": true
  },
  {
    "clause_index": 148,
    "start_char": 59572,
    "end_char": 59739,
    "original": "(i) The Licensee shall cease to use the License and cease to conduct any activities that would require the License, unless explicitly stated otherwise in this Article.",
    "modified": "(ii) The Licensor grants permission for the continued use of the License and any related activities, provided such use or activities are expressly permitted within this Article. Otherwise, the Licensee shall discontinue such actions at their own discretion.",
    "contradiction_score": 0.6596171855926514,
    "kept": true
  },
  {
    "clause_index": 150,
    "start_char": 60230,
    "end_char": 61057,
    "original": "(iii) Promptly upon the request of Licensor, the Licensee shall, at the Licensor\u2019s sole discretion and election for each country of the Territory and each Licensed Product either withdraw or transfer all Marketing Authorizations in the Territory to the Licensor (or to a third party as the Licensor directs). Licensee shall take the required steps without any delay and the withdrawal or transfer shall be completed in maximum 90 days after the notification of the request\u037e if the Licensor does not decide and inform within this period to whom the Marketing Authorizations and documents shall be transferred, then the Licensee shall have no obligation to keep them active. If a Marketing Authorization has been applied for, but not yet been granted in any country of the Territory, the same shall apply to the applicant status.",
    "ollama_generated": "(iii) Upon request by the Licensor, the Licensee shall, at the Licensor's sole discretion and option, within each country of the Territory and for each Licensed Product, either discontinue or assign all Marketing Authorizations within the Territory to the Licensor (or a designated third party). The Licensee will carry out these steps expeditiously, and the process shall be completed no later than 90 days following the notification of the request. If, within this period, the Licensor does not indicate where the Marketing Authorizations and documents should be transferred, the Licensee is relieved of the obligation to maintain their active status. In the event that a Marketing Authorization application has been submitted but not yet approved in any territory of the Territory, the same provisions shall apply to the applicant status.",
    "contradiction_score": 0.0014250691747292876,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 155,
    "start_char": 61929,
    "end_char": 62239,
    "original": "20.2. Notices All notices or other communications to be given under or in connection with this Agreement shall be made in writing and shall be delivered by registered mail or overnight courier service to the address that is mentioned on the cover page of this Agreement or subsequently communicated in writing.",
    "ollama_generated": "20.2. Communications: Any notices or communications required under or relating to this Agreement shall be made in writing, and while we encourage registered mail or overnight courier service for delivery, alternative means such as email with read receipt confirmation, fax, or verified electronic messaging services may also be used, provided that the recipient's current contact information has been duly communicated in writing. The point of delivery shall be deemed to have been reached when the communication is sent, unless an earlier time is specified in such communication.",
    "contradiction_score": 0.07362421602010727,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 160,
    "start_char": 64229,
    "end_char": 64301,
    "original": "20.6. Appendices All Appendices form an integral part of this Agreement.",
    "ollama_generated": "20.6. Appendices: The spirit of this Agreement encompasses the Appendices, though it's acknowledged that they may be consulted or referred to at the discretion of the parties involved.",
    "contradiction_score": 0.022092564031481743,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 162,
    "start_char": 64651,
    "end_char": 64976,
    "original": "21. Governing Law and Jurisdiction This Agreement shall be governed by and construed in accordance with the substantive laws of the Netherlands, excluding its rules of conflicts of law and the United Nations Convention on Contracts for the International Sale of Goods dated 11 April 1980 (CISG), as amended from time to time.",
    "ollama_generated": "21. Governing Law and Jurisdiction: This Agreement is subject to the substantive laws of the Netherlands, but free from its choice of law principles and the United Nations Convention on Contracts for the International Sale of Goods dated 11 April 1980 (CISG), as amended, with regard to any conflict-resolution mechanisms or principles that may apply.",
    "contradiction_score": 0.013009903021156788,
    "kept": false,
    "reason": "low_contradiction"
  },
  {
    "clause_index": 164,
    "start_char": 65390,
    "end_char": 65541,
    "original": "The place of Arbitration shall be in The Hague, Netherlands, or in a place otherwise mutually agreeable. The arbitration shall be conducted in English.",
    "ollama_generated": "The selection of the venue for Arbitration may initially default to The Hague, Netherlands; however, should both parties find it unfeasible, an alternative location mutually acceptable shall be determined. The chosen location shall maintain the usage of English as the language of arbitration proceedings.",
    "contradiction_score": 0.01020961906760931,
    "kept": false,
    "reason": "low_contradiction"
  }
]